Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.5.1.88: peptide deformylase

This is an abbreviated version!
For detailed information about peptide deformylase, go to the full flat file.

Word Map on EC 3.5.1.88

Reaction

formyl-L-methionyl peptide
+
H2O
=
formate
 +
methionyl peptide

Synonyms

AtDEF1.1, AtDEF1.2, AtDEF2, AtPDF1A, AtPDF1B, AtPDF1Bt, AtPDF2, BbPDF, BcPDF, BcPDF2, DEF, Def1, DEF2, deformylase, peptide N-formylmethionine, EC 3.5.1.27, EcPDF, ECPDF1B, EfPDF, HpPDF, HsPDF, hydrolase, aminoacyl-transfer ribonucleate, LiPDF, mPDF, Ni-peptide deformylase, PDF, PDF-1, PDF-2, PDF1A, PDF1B, PDF2, PdfA, PdfB, PdfC, peptide deformylase, peptide deformylase 1, peptide deformylase 1A, peptide deformylase 1B, peptide deformylase 2, Pf PDF, PfPDF, Polypeptide deformylase, SaPDF, sPDF, TbPDF1, TbPDF2, type I PDF, type II PDF, type II peptide deformylase, Vp 16 PDF1B, Vp16 PDF, Vp16T, XOO1075, XoPDF

ECTree

     3 Hydrolases
         3.5 Acting on carbon-nitrogen bonds, other than peptide bonds
             3.5.1 In linear amides
                3.5.1.88 peptide deformylase

Inhibitors

Inhibitors on EC 3.5.1.88 - peptide deformylase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1-hydroxyaminomethyl-2-phenylethyl)carbamic acid tert-butyl ester
AtPDF2
(1-hydroxycarbamoylmethyl-2-phenylethyl)carbamic acid tert-butyl ester
AtPDF2
(2E)-3-(2,5-dihydroxyphenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one
-
(2R)-2-(2-cyclopentylethyl)-N4-hydroxy-N1-[(2S)-1-[(2R)-2-hydroxypyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]butanediamide
-
(2R)-2-[(N-hydroxyformamido)methyl]hexanoic acid
the proteolyzed fragment is bound to the active site
(2R)-N-[(1S)-1-(dimethylcarbamoyl)-2,2-dimethylpropyl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N-[(1S)-5-amino-1-(hexylcarbamoyl)pentyl]-2-[[formyl(hydroxy)amino]methyl]heptanamide
-
(2R)-N-[(2S)-1-(dimethylamino)-3,3-dimethyl-1-oxobutan-2-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
an actinonin derivative
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide
(2R)-N-[(3S)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-4,4-dimethylpent-1-en-3-yl]-2-[[formyl(hydroxy)amino]methyl]hexanamide
(2R)-N-[6-carbamimidamido-1-(naphthalen-2-yl)-2-oxohexan-3-yl]-2-(sulfanylmethyl)hexanamide
-
(2R)-N4-hydroxy-N1-[(2R)-1-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide
-
(2R)-N4-hydroxy-N1-[(2S)-3-methyl-1-oxo-1-(piperidin-1-yl)butan-2-yl]-2-pentylbutanediamide
-
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1R)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[(1S)-1-phenylethyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(trifluoromethyl)-4H-pyrazol-3-yl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-1-{(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl}-N-(5-methyl-1,3-thiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
-
-
(2S)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]pent-4-ynoic acid
-
(2S)-6-amino-2-[(2S)-2-[(hydroxyamino) methyl]hexanamido]-N-phenylhexanamide
the acid hydrolyzed fragment, which exists as a dimer, is characterized as an intersubunit molecule
(2S)-6-amino-2-[(2S)-2-[(N-hydroxyformamido)methyl]hexanamido]-N-phenyl hexanamide
-
(2S)-N-(2-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(2-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(3-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-bromophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-(5-fluoropyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N-cyclopropyl-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-2,5-dihydro-1H-pyrrole-2-carboxamide
(2S)-N1-(2-cyclopentylethyl)-N2-(4,5-dimethyl-1,3-thiazol-2-yl)-N1-[2-(hydroxyamino)-2-oxoethyl]pyrrolidine-1,2-dicarboxamide
-
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylpyridin-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3aR,7aS)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)octahydro-1H-indole-2-carboxamide
(2S,3R,4S,5R,6R)-2-[(5-bromo-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,3R,4S,5S,6R)-2-[(5-bromo-6-chloro-1H-indol-3-yl)oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
-
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methyl-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(2Z)-2-(3-butyl-1,3-benzothiazol-2(3H)-ylidene)-N-hydroxyacetamide
(3R)-3-[3-[(1,3-benzothiazol-2-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
(3R)-3-[3-[(1-benzofuran-3-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-5-cyclopentyl-N-hydroxypentanamide
(3R)-3-[3-[(2H-1,3-benzodioxol-5-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[3-[([1,1'-biphenyl]-4-yl)methyl]-1,2,4-oxadiazol-5-yl]-N-hydroxyheptanamide
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]-N-hydroxyheptanamide
-
(3R)-3-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptanoic acid
-
(3R)-N-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethoxy)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(3-[[4-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazol-5-yl)heptanamide
(3R)-N-hydroxy-3-(4-phenyl-1,3-oxazol-2-yl)heptanamide
(3R)-N-hydroxy-3-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]heptanamide
(3R)-N-hydroxy-3-[3-[(4-methylphenyl)methyl]-1,2,4-oxadiazol-5-yl]heptanamide
(3R)-N-hydroxy-3-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]heptanamide
(4S)-N-[3-chloro-2-(morpholin-4-yl)phenyl]-3-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-1,3-oxazolidine-4-carboxamide
active against Staphylococcus aureus and Streptomyces strains
(5Z)-5-([2-[(E)-2-(dimethylamino)ethenesulfonyl]-6-phenylimidazo[2,1-b][1,3,4]thiadiazol-5-yl]methylidene)-1,3-thiazolidine-2,4-dione
-
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(1H-pyrazol-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(5-methyl-1,3-thiazol-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-(pyridin-3-yl)phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[3-[(pyrimidin-2-yl)amino]phenyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(pyridin-3-yl)pyrimidin-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(1H-benzimidazol-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(3-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(4-fluoropyridin-2-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(6S)-N-(5-tert-butyl-1,2-oxazol-3-yl)-5-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-5-azaspiro[2.4]heptane-6-carboxamide
(E)-1,5-dimethyl-2-phenyl-4-((5-styryl-1,3,4-thiadiazol-2-yl)amino-1,2-dihydro-3H-pyrazole-3-one)
-
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,4-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,5-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2,6-dichlorobenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(2-chlorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4,5-trimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(3,4-dimethoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-chlorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-fluorobenzylidene)thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-(4-methoxybenzylidene) thiazolidine-2,4-dione
-
(E)-3-((20-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5-benzylidenethiazolidine-2,4-dione
-
(E)-5-methyl-N-(5-styryl-1,3,4-thiadiazole-2-yl)isoxazol-3-amine
-
-
(E)-5-styryl-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
-
-
(E)-N-(furan-2-ylmethyl)-5-styryl-1,3,4-thiadiazol-2-amine
-
-
(E)-N-phenethyl-3-(3,4-diacetoxyphenyl)acrylamide
IC50: 0.00125 mM
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid ((S)-5-amino-1-phenylcarbamoyl-pentyl)-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((R)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(R)-2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [(S)-5-amino-1-((S)-2-isopropoxymethyl-pyrrolidine-1-carbonyl)-pentyl]-amide
-
-
(RS)- and (SR)-3-[(RS)-benzenesulfinyl]heptanoic acid hydroxyamide
-
mixture of both components, IC50: 0.0001 mM, possible antimicrobial agent
(RS)-3-(phenylsulfonyl)heptanoic acid hydroxyamide
-
IC50: 0.035 micro molar, possible antimicrobial agent
(S)-1-((R)-2-(((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoro-1-oxido-pyridin)-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(2-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(3-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-bromophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl(hydroxy)amino)methyl)hexanoyl)-N-(4-chlorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((formyl-hydroxyamino)methyl)hexanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-(5-methylthiazol-2-yl)pyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-N-(pyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-Nphenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-((S)-1-phenylethyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-fluoropyridin-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-(5-methylthiazol-2-yl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-N-phenyl-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-2-O-(H-phosphonoxy)-L-caproyl-L-Leu-p-nitroanilide
-
similar inhibition of Fe2+- and Co2+-bound enzyme
(S)-2-O-(phosphonoxy)-L-caproyl-L-leucyl-p-nitroanilide
-
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(S)-N-(4-fluorophenyl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-(5-fluoropyridin-2-yl)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamide
(S)-N-cyclopropyl-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide
(Z)-4-hydroxy-3-(5-((4-(phenyldiazenyl) phenyl) amino)-1,3,4-thiadiazol-2-yl)benzene sulfonic acid
-
-
(Z)-5-(3,4-dimethoxyphenyl)-N-(4-(phenyl diazenyl) phenyl)-1,3,4-thiadiazol-2-amine
-
-
(Z)-N-(4-methylpyridine-2-yl)-5-styryl-1,3,4-thiadiazol-2-amine
-
-
1,10-phenanthroline
1,2-Ethanedithiol
-
irreversible
1,3-propanedithiol
-
irreversible
1,5-pentanedithiol
-
-
1-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl)-4-methylidene-N,N-dimorpholin-4-yl-L-prolinamide
1-(5-bromo-1H-indol-3-yl)-3-hydroxypropan-2-one
AtPDF2
1-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxymethanamine
1-(methylamino)-3-[2-(prop-2-en-1-yl)phenoxy]propan-2-ol
-
1-[(2-methoxyphenyl)carbamoyl]prolyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-methylidene-N-(5-methyl-1,3-thiazol-2-yl)-L-prolinamide
active against Staphylococcus aureus strains
1-[(2R)-2-[(2S)-1-(hydroxyamino)-1-oxopropan-2-yl]hexanoyl]-N-propyl-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(2-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(3-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methoxyphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-methylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-morpholin-4-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-piperidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-(4-pyrrolidin-1-ylphenyl)-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(1H-pyrrol-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-methylpiperazin-1-yl)phenyl]-L-prolinamide
1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-[4-(4-oxidomorpholin-4-yl)phenyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2,2-dimethylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(2-methylpropanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(3-methylbutanoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(cyclopropylcarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(ethylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxyacetyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methoxycarbonyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(methylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-(prop-2-en-1-ylcarbamoyl)-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(2-hydroxyethyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-hydroxypropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(3-phenylpropyl)carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(cyclopentyloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(propan-2-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[(tetrahydro-2H-pyran-4-yloxy)carbonyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(1H-imidazol-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyrazin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-2-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-3-yl)ethyl]carbamoyl]-L-prolinamide
1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-N-[[2-(pyridin-4-yl)ethyl]carbamoyl]-L-prolinamide
1-[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]-N-hydroxymethanamine
2',2'-bisepigallocatechin monogallate
-
-
2,3-dichloro-N-[2-[formyl(hydroxy)amino]ethyl]benzamide
active against Haemophilus influenzae strains
2,3-dimercapto-1-propanesulfonic acid
-
-
2,3-dimercapto-1-propanol
-
-
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoropyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((2S,4S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-methylpyrrolidine-2-carboxamido)-5-fluoropyridine 1-oxide
2-((S)-1-((R)-3-cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-2,5-dihydro-1H-pyrrole-2-carboxamido)-5-fluoropyridine 1-oxide
2-(1-benzyl-5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(1-benzyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.002 mM
2-(1-butyl-5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00059 mM
2-(2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00076 mM
2-(2,2-dioxo-1,4-dihydro-2lambda6,1,3-benzothiadiazin-3(2H)-yl)-N-hydroxyacetamide
2-(2-ethoxy-4-(((4-(3-oxomorpholino)phenyl)amino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0364, 0.120, and 0.0480 mM, respectively
2-(2-ethoxy-4-((morpholinoamino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0096, 0.0679, and 0.0229 mM, respectively
2-(2-ethoxy-4-((pyridin-3-ylamino)methyl)phenoxy)-N-hydroxyacetamide
the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0966, 0.0454, and 0.0136 mM, respectively
2-(3-benzyl-5-bromo-1H-indol-1-yl)-N-hydroxyacetamide
2-(4-benzyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(4-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(4-formyl-3,5-diiodophenyl)-N-hydroxyacetamide
-
2-(4-[2-[(2,5-difluorophenyl)amino]-2-oxoethyl]-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)-N-oxoacetamide
-
2-(5-bromo-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000069 mM
2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.000098 mM
2-(5-bromo-2-methyl-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-bromo-2-methyl-1H-indolyl)-N-hydroxyacetamide
2-(5-bromo-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.000049 mM
2-(5-chloro-1-cyclopropyl-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00011 mM
2-(5-chloro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-chloro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00012 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
inhibitor shows good selectivity for peptide deformylase over several endoproteases including matrix metalloproteases, however it shows only weak antibacterial activity. IC50: 0.00031 mM
2-(5-chloro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide
-
IC50: 0.027 mM
2-(5-fluoro-1H-indol-3-yl)-N-hydroxyacetamide
2-(5-fluoro-2,2-dioxido-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-fluoro-2-oxo-1,4-dihydroquinazolin-3(2H)-yl)-N-hydroxyacetamide
-
IC50: 0.00087 mM
2-(5-methoxy-1H-indol-3-yl)-N-hydroxyacetamide
AtPDF2
2-(6-bromo-1H-indol-3-yl)-N-hydroxyacetamide
2-(biphenyl-4-yl)-N-oxoacetamide
-
2-(indol-3-yl)-N-hydroxyacetamide
2-amino-5-mercapto-1,3,4-thiadiazole
slow-binding inhibitor of PDF when dissolved only in dimethylformamide, but not in any other solvent, and aged (via the formation of a disulfide bond) to a dimeric form
2-amino-N-[(1S,2S)-1-hydroxy-1-phenylpropan-2-yl]-N-methylacetamide
-
2-amino-N-[4-(2,5-dimethoxyphenyl)butyl]ethane-1-sulfonamide
CAP05909402, docking into PfPDF-Co2+-actinonin complex
2-butyl-5,7-dimethyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a class of angiotensin II receptor antagonists, potent inhibitor, IC50: 0.0076 mM
2-hydroxy-4-phenoxybutanal
active against Haemophilus influenzae strains
2-mercaptoethanol
-
30% inhibition at 1 mM
2-oxo-pyrrolidine with chelators
-
-
-
2-phenylethanamine
2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
CAPE, does not chelate HpPDF and does not disrupt the metal-dependent catalysis
2-thioxo-4-thiazolidinone N-hexanoic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00166 mM
2-thioxo-4-thiazolidinones
-
-
-
2-[(12R,17aS)-1,13-dioxohexadecahydro-1H-pyrrolo[1,2-a][1,4]diazacyclopentadecin-12-yl]-N-hydroxyacetamide
-
-
2-[(3-aminopropanoyl)amino]-3-phenylpropanoic acid
-
2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxamide
2-[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]-N-hydroxyacetamide
2-[2,2-dioxido-5-(trifluoromethyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00013 mM
2-[2-chloro-4-([[2-(1H-indol-3-yl)ethyl]amino]methyl)-6-methoxyphenoxy]acetamide
i.e. M7594_0037, the compound exhibits potent anticancer activities against HeLa, A549 and MCF-7 cell lines with IC50s of 0.0353, 0.0296, and 0.0246 mM, respectively
2-[2-[(2-hydroxyethyl)amino]-1H-benzimidazol-1-yl]-1-phenylethanone
-
2-[4-(3,3-dimethyl-2-oxobutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(3-methylbutyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-oxoacetamide
-
2-[5-chloro-2,2-dioxido-1-(3-phenylpropyl)-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl]-N-hydroxyacetamide
-
IC50: 0.00029 mM
2-[[formyl(hydroxy)amino]methyl]-N-[(5-methoxy-1H-benzimidazol-2-yl)methyl]hexanamide
3,3,3-trifluoro-N-[(2S)-1-[formyl(hydroxy)amino]-3-phenylpropan-2-yl]propanamide
3-(3-acetylsulfanyl-2-oxopropyl)indole-1-carboxylic acid benzyl ester
AtPDF2
3-(5-((4H-1,2,4-triazol-4-yl)amino)-1,3,4-thiadiazol-2-yl)-4-hydroxy benzenesulfonic acid
-
-
3-(5-((furan-2-ylmethyl)amino)-1,3,4-thiadiazole-2-yl)-4-hydroxybenzenesulfonic acid
-
-
3-(5-[(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino]-4H-1,2,4-triazol-3-yl)-4-hydroxybenzenesulfonic acid
-
-
3-carboxymethylindol-1-carboxylic acid benzyl ester
AtPDF2
3-methoxy-7-methyl-1,3-dihydro-2-benzofuran-4,5,6-triol
has antibacterial activity on Staphylococcus aureus strains
3-methoxycatechol
-
-
3-methyl-N-(1,3-thiazol-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(2-methylpropanoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(morpholin-4-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(phenylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(piperidin-1-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-2-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-3-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(pyridin-4-ylcarbamoyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-(thiophen-2-ylcarbonyl)-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-methyl-N-[methyl(phenyl)carbamoyl]-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
3-[5'-benzyl-2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
-
potent inhibitor, IC50: 0.0342 mM, the acidic moiety forms direct ionic interactions with active site metal cation
4'-((2-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-fluoro-4-morpholinophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((3-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-(trifluoromethyl)phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-carboxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-chloro-2-nitrophenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4-hydroxyphenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((4H-1,2,4-triazol-4-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-((6-methoxybenzothiazol-2-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-((phenylamino)methyl)biphenyl-2-carbonitrile
-
4'-((pyrazin-2-ylamino)methyl)biphenyl-2-carbonitrile
-
4'-(2-ethyl-6,8-dimethylimidazo[1,2-b]pyridazin-3-yl)[1,1'-biphenyl]-2-carboxylic acid
-
4'-([(5Z)-2,4-dioxo-5-[(3,4,5-trimethoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,4-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,5-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2,6-dichlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(2-chlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-chlorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-fluorophenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-([(5Z)-5-[(4-methoxyphenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)[1,1'-biphenyl]-2-carbonitrile
-
4'-[(2-ethyl-6,8-dimethyl-3,5-dihydroimidazo[1,2-b]pyridazin-3-yl)methyl][1,1'-biphenyl]-2-carboxylic acid
-
4'-[[(5Z)-5-benzylidene-2,4-dioxo-1,3-thiazolidin-3-yl]methyl][1,1'-biphenyl]-2-carbonitrile
-
4-((5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazol-2-yl)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
-
-
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl hydrogen carbonate
4-([5-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,2,4-oxadiazol-3-yl]methyl)phenyl methyl carbonate
4-amino-3-[[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl]sulfanyl]-6-methyl-1,2,4-triazin-5(4H)-one
CAP01891052, docking into PfPDF-Co2+-actinonin complex
4-hydroxy-3-(5-((5-methylisoxazol-3-yl)amino)-1,3,4-thiadiazol-2-yl)benzenesulfonic acid
-
-
4-hydroxy-3-(5-[(4-methylpyridin-2-yl)amino]-4H-1,2,4-triazol-3-yl)benzenesulfonic acid
-
-
4-methyl-1,3-dihydro-2-benzofuran-1,5,6,7-tetrol
has antibacterial activity on Staphylococcus aureus strains
4-[(Z)-[3-(2-chlorobenzoyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]-N-(4-phenyl-1,3-thiazol-2-yl)benzene-1-sulfonamide
-
5'-phosphothiorate modified antisense oligodeoxyribonucleotides
-
-
-
5,5'-disulfanediyldi(1,3,4-thiadiazol-2-amine)
dimerization of two 2-amino-5-mercapto-1,3,4-thiadiazole molecules via the dithiol linkage forming bis-AMT
5-(3,4-dimethoxyphenyl)-N-(4-methylpyridine-2-yl)-1,3,4-thiadiazol-2-amine
-
-
5-(3,4-dimethoxyphenyl)-N-(4H-1,2,4-triazol-4-yl)-1,3,4-thiadiazol-2-amine
-
-
5-(3,4-dimethoxyphenyl)-N-(furan-2-ylmethyl)-1,3,4-thiadiazol-2-amine
-
-
5-([[(1-benzothiophen-2-yl)methyl]sulfanyl]methyl)-N-hydroxy-1,2-oxazole-3-carboxamide
poor antibacterial activity
5-amino-1,3,4-thiadiazole-2-thiol
a slow-binding inhibitor of Escherichia coli Ni-PDF inhibitor upon aging
5-bromo-3-hydroxycarbamoylmethylindole-1-carboxylic acid benzyl ester
5-bromo-7-methyl-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-3H-imidazo[4,5-b]pyridine
-
5-chloro-2-propyl-3-[2''-(1H-tetrazol-5-ylmethyl)-[1,1',4',1'']terphenyl-4-yl]-3H-imidazo[4,5-b]pyridine
-
belongs to a broad class of angiotensin II receptor antagonists, potent competitive inhibitor, IC50: 0.0039 mM, the acidic moiety forms direct ionic interactions with active site metal cation
5-chloro-2-propyl-3-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-3H-imidazo[4,5-b]pyridine
-
5-fluoro-2-((2S,4S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylpyrrolidine-2-carboxamido)pyridine 1-oxide
5-fluoro-2-((2S,4S)-4-fluoro-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)pyrrolidine-2-carboxamido)pyridine1-oxide
5-fluoro-2-((S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylenepyrrolidine-2-carboxamido)pyridine 1-oxide
5-[[(2-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3,4-dichlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(3-chlorophenyl)sulfonyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
-
5-[[(4-chlorophenyl)sulfanyl]methyl]-N-hydroxy-1,2-oxazole-3-carboxamide
5-[[(4-methoxyphenyl)sulfonyl]methyl]-1,2-oxazole-3-carbohydrazide
-
6,7-dibromo-3-(3,4-dimethoxy-5-methylbenzoyl)-1-benzofuran-4(5H)-one
-
6,7-dichloro-3-(3,4-dimethoxybenzoyl)-1-benzofuran-4,5-dione
-
6-chloro-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-benzimidazole
7,8-dihydroxyflavone
-
-
8-hydroxyquinoline
-
50% inhibition at 2 mM
actinonin
aldehyde peptide
-
IC50 against Escherichia coli peptide deformylase: 0.01 mM
-
alkyl-succinate-proline hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000004-0.000010 mM
analogues of actinonin
-
35 different compounds were synthesized and compared to the inhibitory activity of actinonin
-
BB-3497
BB-81384
BB-83698
BB83698
benzimidazole N-formyl hydroxylamine
-
-
benzothiazinone derivatives
-
IC50: 0.000005 mM
-
benzothiazolylidene hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.00104 mM
-
benzyl 5-bromo-3-[2-(hydroxyamino)-2-oxoethyl]-1H-indole-1-carboxylate
beta-sulfonylhydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.000016 mM
butyl {[4'-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)-5-(2-methylbutan-2-yl)biphenyl-2-yl]sulfonyl}carbamate
-
competitive inhibition, IC50: 0.015 mM, the acidic moiety forms direct ionic interactions with active site metal cation
caffeic acid phenethyl ester
-
CAPE, an active component of propolis, 75% inhibition at 0.01 mM, the competitive inhibitor blocks the substrate entrance, preventing substrate from approaching the active site, but CAPE does not have chelate interaction with HpPDF and does not disrupt the metal-dependent catalysis
calpeptin
carbamate N-formyl hydroxylamine
-
-
chloranil
-
-
Ciprofloxacin
Co(III)1
-
peptide cleaving catalyst
cryptochlorogenic acid
with high score in enzyme docking analysis
Diethylenetriaminepentaacetic acid
dihydromyricetin
with high score in enzyme docking analysis
diprop-2-en-1-yl (2S)-2-aminobutanedioate
-
drechmerin I
an antibacterial compound, isolated from the fermentation broth of Drechmeria sp. strain SYPF 8335, which is isolated from the inside root of Panax notoginseng, from Wenshan district, Yunnan province of China. Compound structure determination by mass spectrometry and 1H and 13C NMR. Molecular docking in the active site of PDF from Staphylococcus aureus through the hydrogen bonds with Try88 and Arg143. Drechmerin I displays antimicrobial activity against Bacillus subtillis with an MIC value of 0.2 mg/ml
epigallocatechin 3,5-digallate
-
-
epitheaflavin monogallate
-
-
ethyl 1-(N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]heptanoyl]-L-valyl)piperidine-3-carboxylate
-
ethyl 2-(2-ethoxy-4-(((4-(3-oxomorpholino)phenyl)amino)methyl)phenoxy)acetate
-
ethyl 2-(2-ethoxy-4-((morpholinoamino)methyl)phenoxy)acetate
-
ethyl 2-(2-ethoxy-4-formylphenoxy)acetate
-
ethyl 2-amino-3-(benzylsulfanyl)propanoate
-
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate
-
ethyl 2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carboxylate
Fe3+
-
inactivation due to oxidation of Fe2+ to Fe3+
flavimycin A
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
flavimycin B
-
a dimeric 1,3-dihydroisobenzofuran, isolated from cultures of Aspergillus flavipes, structure analysis by NMR and mass spectrometry, the inhibitor exists as epimeric mixture at C-1 through fast hemiacetal-aldehyde tautomerism. The compound has antibacterial activity against Staphylococcus aureus including MRSA, with MIC values of 0.032-0.064 mg/mL
formylmethionine
-
fumimycin
gentiopicroside
with high score in enzyme docking analysis
glutathione
-
10% inhibition at 1 mM
GSK-1322322
GSK1322322
hematein
-
-
hematoxylin
heteroarylaryl(P2'/P3')N-formyl hydroxylamine
-
-
hydantoin
-
IC50 against Escherichia coli peptide deformylase: 0.0002 mM
hydrazide N-formyl hydroxylamine
-
-
imino[(5-methoxy-5-oxo-4-[2-(sulfanylmethyl)hexanoyl]aminopentyl)amino]methaneamine
irigenol
-
-
isoxazole-3-hydroxamic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.0034 mM
-
isoxazole-3-hydroxamic acids
-
LBM-415
LBM415
linezolid
macrolactin N
methyl (3R)-3-[2-(4-carbamoylpiperidin-1-yl)acetamido]-4-chloro-3H-indole-2-carboxylate
IBS297042, docking into PfPDF-Co2+-actinonin complex
methyl 3-[(8-methyl-2,3-dihydrofuro[3,2-e]imidazo[1,2-c]pyrimidine-9-carbonyl)amino]thiophene-2-carboxylate
CD1691700, docking into PfPDF-Co2+-actinonin complex
methyl 4-(2-benzylbenzoyl)-2,5-dimethyl-1H-pyrrole-3-carboxylate
-
methyl N-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinate
methyl-1-(sulfanylmethyl)hexanoate
N-((5-bromo-2-methyl-1(phenylsulfonyl)-1H-indol-3-yl)methyl) hydroxylamine
AtPDF2
N-((R)-2-(cyclopentylmethyl)-3-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrol-1-yl)-3-oxopropyl)-N-hydroxyformamide
N-(1-benzenesulfonyl-5-bromo-2-methyl-1H-indol-3-ylmethyl)-N-hydroxyformamide
N-(2-methoxybenzoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(2-[[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(4-hydroxyphenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(2-[[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl]hexyl)-N-hydroxyformamide
N-(3,4-difluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-2,4-dimethylphenyl)-1-[(2S)-2-[(1S)-2-(hydroxyamino)-1-(hydroxysulfanyl)-2-oxoethyl]hexanoyl]-L-prolinamide
-
N-(3-chloro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-chloro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-morpholin-4-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-piperidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-fluoro-4-pyrrolidin-1-ylphenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloheptadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclohexadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cycloicos-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl)-methyl-N-hydroxy-formamide
-
N-(3-tert-butyl-2,5-dioxo-1,4-diaza-cyclotridec-6-yl)-methyl-N-hydroxy-formamide
-
N-(4-((Z)-phenyldiazenyl) phenyl)-5-((Z)-styryl)-1,3,4-thiadiazol-2-amine
-
-
N-(4-chlorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(4-fluorophenyl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(4-nitrophenyl)-N2-[2-(sulfanylmethyl)hexanoyl]lysinamide
-
N-(5-(3,4-dimethoxy phenyl)-1,3,4-thiadiazol-2-yl)-5-methylisoxazol-3-amine
-
-
N-(5-chloro-2,4-dimethoxyphenyl)-2-(4-ethyl-6-oxo-2-phenylpyrimidin-1(6H)-yl)acetamide
VIT1024538, docking into PfPDF-Co2+-actinonin complex
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide
N-(5-fluoro-1-oxidopyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-(benzylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(benzyloxy)-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-(cyclobutylcarbamoyl)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-L-prolinamide
active against Staphylococcus aureus, Haemophilus influenzae, and Streptomyces pneumoniae strains
N-(cyclobutylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclobutylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclohexylcarbamoyl)-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-(cyclohexylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(cyclopentylcarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(R)-[2-(hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine amide
-
-
N-(tert-butoxycarbonyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-(tert-butylcarbamoyl)-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-acetyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-alkyl urea hydroxamate
-
IC50 against Escherichia coli peptide deformylase: 0.000003 mM
N-benzoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-benzoyl-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-benzyloxycarbonyl-Leu-norleucinal
N-carbamoyl-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-formyl-L-methionylalanine
-
inhibition above 4 mM
N-formyl-Met-Ala-Ser
-
the enzyme activity of truncated PDF-1DeltaN37 is inhibited by an excess of N-formyl-Met-Ala-Ser substrate
N-formyl-N-hydroxy-2-(3-benzoylphenoxy)ethylamine
N-formyl-N-hydroxy-3-phenylpropylamine
N-formylhydroxylamine
-
i.e. LBM-415
N-hydroxy urea
-
IC50 against Escherichia coli peptide deformylase: 0.0022 mM
N-hydroxy-2-(1H-indol-3-yl)acetamide
N-hydroxy-2-(2-oxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide
N-hydroxy-2-(3-oxo-3,4-dihydro-2H-1,3lambda4,2,4-benzodithiadiazin-2-yl)acetamide
-
N-hydroxy-2-(5-methoxy-1H-indol-3-yl)acetamide
N-hydroxy-2-(substituted phenyl) acetamide
-
-
N-hydroxy-2-[2-oxo-5-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl]acetamide
-
IC50: 0.00023 mM
N-hydroxy-5-([[2-(propan-2-yl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-5-([[4-(trifluoromethyl)phenyl]sulfanyl]methyl)-1,2-oxazole-3-carboxamide
-
N-hydroxy-N-((R)-2-((S)-2-(morpholine-4-carbonyl)-2,5-dihydro-1H-pyrrole-1-carbonyl)hexyl)formamide
N-hydroxy-N-((R)-2-((S)-4-methylene-2-(morpholine-4-carbonyl)pyrrolidine-1-carbonyl)hexyl)formamide
N-hydroxy-N-(3-hydrazino-3-oxopropyl)formamide
-
-
N-hydroxy-N-[(2R)-2-[[(2S)-2-(morpholin-4-ylcarbonyl)-2,5-dihydro-1H-pyrrol-1-yl]carbonyl]hexyl]formamide
N-hydroxy-N-[3-(6-methylpyridine-2-yl)propyl]formamide
N-hydroxy-N2-[(1-hydroxycyclopentyl)(phenyl)acetyl]valinamide
-
N-methoxy-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-methoxy-N-methyl-2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl)acetamide
-
N-oxo-2-[3-oxo-4-(2-phenylethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-(tetrahydro-2H-pyran-2-ylmethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-oxo-2-[3-oxo-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamide
-
N-substituted methionine hydrazide
-
IC50 against Escherichia coli peptide deformylase: 0.2 mM
N-sulfonyl-L-Val-L-Leu-hydroxamate
-
-
N-trans-caffeoyltyramine
IC50: 0.0108 mM
N-[(2-aminoethyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(2-methoxyethyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N-hydroxy-N2-(3-methylbutyl)glycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(2-cyclopentylethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclobutylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
N-[(2-methoxyphenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopropylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]alanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]leucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]norleucyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]phenylalanyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2-methoxyphenyl)carbamoyl]valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
N-[(2R)-2-(cyclopentylmethyl)-3-(2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl]hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide
N-[(2R)-2-(cyclopentylmethyl)-3-[2-(furan-2-carbonyl)-1,2-diazinan-1-yl]-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide
-
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]heptyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]hexyl]-N-hydroxyformamide
-
N-[(2R)-2-[[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]carbonyl]pentyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1,3-benzoxazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R)-3-[(2S)-2-(1H-benzimidazol-2-yl)pyrrolidin-1-yl]-2-benzyl-3-oxopropyl]-N-hydroxyformamide
-
N-[(2R,4S)-2-butyl-4-[[(2-fluorophenyl)carbamoyl]amino]-5-methyl-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(2R,4S)-2-butyl-5-methyl-4-[[(5-methylpyridin-2-yl)carbamoyl]amino]-3-oxohexyl]-N-hydroxyformamide
-
binding structure, overview
N-[(2S)-2-[(2R)-2-(1,3-benzoxazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
active against Mycobacterium tuberculosis strains
N-[(2S)-2-[(2R)-2-(1H-benzimidazol-2-yl)pyrrolidine-1-carbonyl]hexyl]-N-hydroxyformamide
active against Mycobacterium tuberculosis strains
N-[(3,5-difluorophenyl)carbamoyl]-3-methyl-L-valyl-N2-(cyclopentylmethyl)-N-hydroxyglycinamide
-
binding structure, overview
N-[(3,5-difluorophenyl)carbamoyl]-3-methyl-L-valyl-N2-cyclopentyl-N-hydroxyglycinamide
cytotoxic IC50 values for compound PMT497 are 0.0209 mM against MDA-MB-231 and 0.0212 mM against MDA-MB-468 cell lines
N-[(3-amino-3-oxopropyl)carbamoyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(4-formyl-3,5-diiodophenyl)methyl]-N-hydroxyformamide
-
N-[(cyclobutyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[(cyclohexyloxy)carbonyl]-1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolinamide
N-[2-(5-bromo-2-methyl-1H-indole-3-yl)methyl]hydroxylamine
AtPDF2
N-[2-(cyclopentylmethyl)-3-[(2S)-2-[(1,3-dicyclopropyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]-3-oxopropyl]-N-hydroxyformamide
N-[2-([(2S)-2-[(1,3-diphenyltriazan-2-yl)carbonyl]-4-methylidenepyrrolidin-1-yl]carbonyl)hexyl]-N-hydroxyformamide
N-[3-(4-acetamidobutyl)-2,5-dioxo-1,4-diaza-cyclopentadec-6-yl]methyl-N-hydroxy-formamide
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacycloicos-6-yl]methyl-N-hydroxyformamide
-
N-[3-(4-aminobutyl)-2,5-dioxo-1,4-diazacyclopentadec-6-yl]methyl-N-hydroxyformamide
-
N-[3-chloro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1-oxidopiperidin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(1H-pyrrol-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-fluoro-4-(4-oxidomorpholin-4-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[3-[(2S)-2-[[1,3-bis(4-fluorophenyl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoro-1-oxidopyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-fluoropyridin-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[3-[(2S)-2-[[1,3-bis(5-methyl-1,3-thiazol-2-yl)triazan-2-yl]carbonyl]-4-methylidenepyrrolidin-1-yl]-2-(cyclopentylmethyl)-3-oxopropyl]-N-hydroxyformamide
N-[4'-(2-cyclopropyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)[1,1'-biphenyl]-2-sulfonyl]benzamide
-
N-[4-(4-ethylpiperazin-1-yl)-3-fluorophenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(4-ethylpiperazin-1-yl)phenyl]-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-L-prolinamide
N-[4-(trifluoromethyl)benzoyl]-L-Met
-
time-dependent inhibition of zinc and cobalt deformylase, inhibition of full-length Co-PDF is competitive
N-[4-(trifluoromethyl)benzoyl]-L-Met hydrazide
-
time-dependent inhibition of zinc and cobalt deformylase
N-[[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]methyl]-N-hydroxyacetamide
-
N-[[(3S,6R)-3-tert-butyl-2,5-dioxo-1,4-diazacyclopentadecan-6-yl]methyl]-N-hydroxyformamide
-
Zn-BbPDF1-HT
N-[[5-bromo-2-methyl-1-(phenylsulfonyl)-1H-indol-3-yl]methyl]-N-hydroxyformamide
N2-(2-[[formyl(hydroxy)amino]methyl]hexanoyl)-N-phenyl-L-lysinamide
-
N2-(benzenesulfinyl)-N2-butyl-N-hydroxyglycinamide
-
N2-(benzenesulfonyl)-N2-butyl-N-hydroxyglycinamide
-
N2-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]-N-phenyl-L-lysinamide
-
N2-[(2R)-2-[[hydroxy(oxo)-lambda5-phosphanyl]oxy]hexanoyl]-N-(4-nitrophenyl)-D-leucinamide
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxohexan-2-yl]-L-leucinamide
-
N2-[2-[(3R)-1-(hydroxyamino)-1-oxoheptan-3-yl]-1,3-oxazole-4-carbonyl]-L-valinamide
naphthalen-1-yl[[3-(trifluoromethyl)benzyl]amino]acetic acid
-
p-chloromercuribenzoate
-
potent inhibitor, IC50: 0.07 mM
penicillin
Peptide aldehydes
Phe-Arg-beta-naphthylamide
-
-
piperidin-4-yl [1-[(2R)-3-cyclopentyl-2-[[formyl(hydroxy)amino]methyl]propanoyl]-L-prolyl]carbamate
Polyethylene glycol
-
-
polylethylene glycol
-
competitive inhibitor with respect to formylmethionine
-
propan-2-amine
protosappanin B
with high score in enzyme docking analysis
pseudopeptide metabolites
-
IC50 against Escherichia coli peptide deformylase: 0.000030 mM
-
puppurogallin
-
purpurogallin
-
-
pyrogallin
-
-
pyrrolidine bicyclic(P2'/P3')compounds
-
-
-
quinalizarin
-
-
quinazoline hydroxamic acid
-
IC50 against Escherichia coli peptide deformylase: 0.00012 mM
reverse hydroxamate
British Biotech BB-83698
reverse hydroxamates
-
-
-
siRNA HsPDF 581-601
transfection of HeLa cells
-
siRNA HsPDF 659-679
transfection of HeLa cells
-
SKI-AC-1
IC50: 0.000072 mM, actionin analog
SKI-AC-10
IC50: 0.000078 mM, actionin analog
SKI-AC-11101
IC50: 0.000076 mM, actionin analog
-
SKI-AC-111101
IC50: 0.0000600 mM, actionin analog
SKI-AC-111110
IC50: 0.000427 mM, actionin analog
-
SKI-AC-111111
IC50: 0.000069 mM, actionin analog
SKI-AC-111112
IC50: 0.000234 mM, actionin analog
-
SKI-AC-111113
IC50: 0.000177 mM, actionin analog
-
SKI-AC-111114
IC50: 0.000300 mM, actionin analog
-
SKI-AC-11112
IC50: 0.000365 mM, actionin analog
-
SKI-AC-11113
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11114
IC50: 0.000276 mM, actionin analog
-
SKI-AC-11115
IC50: 0.000473 mM, actionin analog
-
SKI-AC-11116
IC50: 0.000335 mM, actionin analog
-
SKI-AC-11117
IC50: 0.000086 mM, actionin analog
SKI-AC-11118
IC50: 0.000115 mM, actionin analog
SKI-AC-11119
IC50: 0.000134 mM, actionin analog
-
SKI-AC-11128
IC50: 0.000522 mM, actionin analog
-
SKI-AC-11138
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11148
IC50: 0.0000600 mM, actionin analog
-
SKI-AC-11158
IC50: 0.000500 mM, actionin analog
-
SKI-AC-11168
IC50: 0.000192 mM, actionin analog
-
SKI-AC-11178
IC50: 0.000200 mM, actionin analog
-
SKI-AC-11188
IC50: 0.000120 mM, actionin analog
SKI-AC-11198
IC50: 0.000090 mM, actionin analog
SKI-AC-3
IC50: 0.000500 mM, actionin analog
-
SKI-AC-5
IC50: 0.000400 mM, actionin analog
-
SKI-AC-51121
IC50: 0.000400 mM, actionin analog
-
SKI-AC-6
IC50: 0.000097 mM, actionin analog
SKI-AC-8
IC50: 0.000093 mM, actionin analog
SKI-AC-9
IC50: 0.000151 mM, actionin analog
-
SKI-AC-I-18
IC50: 0.000404 mM, actionin analog
-
SKI-AC-I-19
IC50: 0.000239 mM, actionin analog
-
tert-butyl 1-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]hexanoyl]-L-prolinate
theaflavin
theaflavin monogallate
-
-
thio peptide
-
IC50 against Escherichia coli peptide deformylase: 0.000019 mM, thiol chelating group combined with the best substrate motif
-
thioacetic acid S-[3-(5-bromo-1H-indol-3-yl)-2-oxopropyl] ester
AtPDF2
thioacetic acid S-[3-(indol-3-yl)-2-oxopropyl] ester
AtPDF2
thiol peptide
-
IC50 against Escherichia coli peptide deformylase: 0.0025 mM, designed based on the best substrate identified
-
Thiophenol
-
IC50: 0.5 mM
thiram
-
-
thyropropic acid derivatives
-
IC50 against Escherichia coli peptide deformylase: 0.001 mM
-
urea analogs(P2'/P3')of N-formyl hydroxylamine
-
-
Vancomycin
VIC-104959
VRC-3375
VRC-4307
ZINC00323509
-
ZINC03088016
-
ZINC03984371
-
ZINC04992698
-
ZINC08740166
-
ZINC12652500
-
ZINC12658529
-
ZINC12660672
-
ZINC12876445
-
[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]acetic acid
-
additional information
-